Low HDL-C, High CRP Ups Mortality for Patients With CAD

This article originally appeared here.
Share this content:
Low HDL-C, High CRP Ups Mortality for Patients With CAD
Low HDL-C, High CRP Ups Mortality for Patients With CAD

TUESDAY, Sept. 15, 2015 (HealthDay News) -- For patients with coronary artery disease (CAD) on statin therapy after undergoing a first percutaneous coronary intervention (PCI), the risk of all-cause mortality is increased with low high-density lipoprotein cholesterol (HDL-C) levels and elevated C-reactive protein (CRP), according to a study published in the Oct. 1 issue of The American Journal of Cardiology.

Manabu Ogita, M.D., Ph.D., from Juntendo University Shizuoka Hospital in Japan, and colleagues examined the impact of inflammation on the correlation between HDL-C and long-term outcomes in patients with CAD on statin therapy. A total of 3,507 consecutive patients with CAD who underwent a first PCI from 1997 to 2011 were enrolled. The 1,682 patients who had been treated with statins at the time of PCI were stratified into four groups according to HDL-C and CRP levels. Patients were followed for a median of 1,985 days.

The researchers found that 11.7 percent of patients died because of cardiac death, carcinoma, stroke, and other causes during follow-up. Among the groups, the rates of all-cause death varied significantly. Even after adjustment for other covariates, low HDL-C with high CRP levels remained significantly associated with a higher rate of all-cause death (hazard ratio, 2.38).

"Low HDL-C together with elevated CRP levels is significantly associated with long-term outcomes in patients who received statin therapy after PCI," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »